H2N2 HA Specific Neutra™ Antibody Products

Facing challenges with low-affinity binding to divergent H2 strains, inconsistent assays, or limited tools for epitope mapping? Creative Biolabs' H2N2 HA specific Neutra™ antibody products deliver precise, reliable results. Our high-affinity, validated antibodies leverage advanced protein engineering and high-throughput B-cell cloning to enable superior detection and functional analysis of H2N2 HA.

Introduction to H2N2 HA

The Hemagglutinin protein of the Influenzavirus A Subtype H2N2 (H2N2 HA) remains a focal point of global virology due to its historical impact and continued pandemic potential. As the primary surface glycoprotein of the virus, it serves as the master key for cellular entry and the primary target for the host's adaptive immune system.

• Basic Characteristics

H2N2 HA is a class I integral membrane glycoprotein responsible for the "Asian Flu" pandemic of 1957. Although it has not circulated in humans since 1968, it persists in avian reservoirs. Because the global population born after that era lacks pre-existing immunity to this subtype, H2N2 HA is classified as a high-priority antigen for the development of "universal" influenza vaccines and preemptive therapeutic antibodies to mitigate zoonotic spillover risks.

• Structure

The H2N2 HA molecule is a homotrimer, with each monomer synthesized as a precursor (HA0) that must be proteolytically cleaved into two subunits: HA1 and HA2. The globular head (HA1) contains the highly variable sialic acid receptor-binding site (RBS), which is the primary target for neutralizing antibodies. In contrast, the stalk or stem region (HA2) is significantly more conserved across different influenza strains and contains the hydrophobic fusion peptide, which is essential for merging the viral and host membranes.

Distributed under the public domain, from Wiki, without modification. Fig.1 3D structure of H2N2.

• Function

H2N2 HA serves a dual functional role. First, it facilitates viral attachment by binding to α2-6 linked sialic acid receptors in the human upper respiratory tract or α2-3 linked receptors in the avian gut. Second, upon internalization into the host cell via endocytosis, the acidic environment of the endosome triggers an irreversible conformational change in HA, allowing the HA2 subunit to mediate the fusion of viral and host membranes.

• Related Signaling Pathways
  • Receptor-Mediated Endocytosis Path: The binding of H2N2 HA to sialic acids initiates clathrin-dependent or independent internalization. This process triggers the recruitment of adaptor proteins and dynamin-mediated scission, moving the virus into the early endosomal compartment, where acidification begins.
  • Acid-Triggered Fusion Cascade: As endosomes mature, the drop in pH to approximately 5.0–6.0 induces a massive structural rearrangement of the HA trimer. The HA1 heads displace, and the HA2 fusion peptide is "shot" into the endosomal membrane, forming a six-helix bundle that creates a fusion pore for viral RNA release.
  • Pro-inflammatory NF-κB Activation: Viral entry and subsequent sensing of viral RNA by TLRs or RIG-I activate the B kinase complex. This leads to the translocation of NF-κB to the nucleus, promoting the transcription of pro-inflammatory cytokines such as TNF-α and IL-6, often leading to hypercytokinemia.
  • MAPK/ERK Pathway Modulation: Influenza infection often hijacks the Mitogen-Activated Protein Kinase (MAPK) pathway. HA-mediated entry can stimulate the Raf/MEK/ERK cascade, which the virus utilizes to support its replication cycle, specifically aiding the nuclear export of viral ribonucleoproteins.

• Related Diseases

H2N2 HA is the defining antigen for pandemic influenza, characterized by high fever, severe respiratory distress, and a high incidence of secondary bacterial pneumonia. In severe cases, the infection progresses to acute respiratory distress syndrome (ARDS), cytokine storm syndrome, and systemic multi-organ failure.

Applications of H2N2 HA Neutralizing Antibodies

• Prophylactic Passive Immunization

High-potency neutralizing antibodies can be administered to high-risk individuals or healthcare workers to provide immediate, short-term protection during a localized H2N2 outbreak. This approach is particularly effective for immunocompromised patients who may not mount a sufficient response to traditional active vaccination.

• Therapeutic Neutralization of Viral Load

For patients already exhibiting clinical symptoms, these antibodies function by binding to the HA1 head domain, physically obstructing the receptor-binding site. By preventing the virus from infecting new cells, these biologics significantly reduce the overall viral load and shorten the duration of disease severity.

• Inhibition of Membrane Fusion

Antibodies targeting the conserved HA2 stem region can prevent the pH-induced conformational change. This effectively "locks" the virus in its pre-fusion state even after endosomal internalization, offering a broad-spectrum protection mechanism that is less susceptible to antigenic drift.

• Standardization of Vaccine Potency

In vaccine manufacturing and quality control, H2N2 HA-specific antibodies are used in Single Radial Immunodiffusion (SRID) and ELISA assays. They allow manufacturers to quantify the exact amount of functional, correctly folded HA protein in each dose, ensuring consistency and efficacy across global production batches.

• Diagnostic Surveillance and Monitoring

Monoclonal antibodies are integrated into rapid diagnostic tests and biosensors to distinguish H2N2 from seasonal H1N1 or H3N2 strains. This differentiation is critical for real-time epidemiological monitoring of zoonotic spillover events and informs public health decision-making during suspected outbreaks.

Our Anti-H2N2 HA Antibodies

Creative Biolabs provides an elite portfolio of H2N2 HA specific Neutra™ antibodies, meticulously engineered to facilitate high-precision influenza research. Our collection includes high-performance monoclonal antibodies (mAbs) validated for diverse experimental workflows, from structural biology to therapeutic lead discovery.

• Comprehensive Domain Targeting: We offer specialized antibodies specific to both the HA1 globular head and the conserved HA2 stalk domain, enabling researchers to investigate diverse mechanisms of viral neutralization.
• Extensive Application Validation: Our H2N2 HA antibodies are rigorously tested for performance in ELISA, Western Blot (WB), Immunofluorescence (IF), and Immunohistochemistry (IHC), ensuring reliable results across varied platforms.
• Superior Binding Kinetics: Utilizing advanced B-cell cloning and phage display, our antibodies demonstrate ultra-low dissociation constants (K_D), providing the sensitivity required for detecting low-abundance viral antigens.
• Optimized for Functional Assays: Selected clones are specifically validated for Hemagglutination Inhibition (HI) and virus neutralization, acting as potent tools for blocking viral entry and membrane fusion.
• Scalable and High-Purity Production: All antibodies are produced under stringent quality control, offering batch-to-batch consistency and low-endotoxin profiles suitable for both in vitro and in vivo applications.

Creative Biolabs offers industry-leading H2N2 HA specific Neutra™ antibody products designed to accelerate your influenza research and therapeutic discovery. For detailed technical specifications or to request a quote, please contact our expert team.